Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
News|Articles|April 14, 2026
Insights in Treating Anxiety and the Pharmaceutical Perspective
Author(s)Freda Lewis-Hall, MD, Jessica Walters
A pharma expert and clinician shares perspectives on developing treatments.
Advertisement
Advertisement
Freda Lewis-Hall, MD, a clinician with extensive experience in practice and pharmaceutical development surveyed the persistent unmet need in anxiety and depression treatment. We spoke with Lewis-Hall to learn more about the pipeline of novel serotonergic agonists, particularly HLP-004 for generalized anxiety disorder and HLP003 for major depressive disorder, which recently showed positive results.1,2 HLP-004 is an investigational intramuscular deuterated serotoninergic agonist, being developed for treatment resisted anxiety.2
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
The menopause transition carries a 2-fold increased risk of depression, and an expert explains how clinicians can screen for it, tell it apart from other conditions, and treat it.
Check out our pipeline updates from September!
A cross-sector ACNP task force calls for shared standards and shared data to move psychiatry beyond trial-and-error prescribing.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Advertisement
Advertisement